



Otonomy to Participate in the H.C. Wainwright BioConnect Conference

January 3, 2022

SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its participation in the H.C. Wainwright BioConnect Virtual Conference. A pre-recorded company presentation by the Otonomy management team will be available on the conference website beginning at 7 a.m. ET / 4 a.m. PT on January 10, 2022.

A link to the presentation will also become available at the same time through the Events page of the company's website (www.otonomy.com).

About Otonomy

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs with a focus on hearing loss and tinnitus. For additional information please visit www.otonomy.com.

Contacts:

Media Inquiries:

Spectrum Science

Chloé-Anne Ramsey

Vice President

404.865.3601

cramsey@spectrumsience.com

Investor Inquiries:

Westwicke ICR

Robert H. Uhl

Managing Director

858.356.5932

robert.uhl@westwicke.com



Source: Otonomy, Inc.